Loading...

Home
Stock
RGC

RGC Overview

-

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

Overview Stock Price Prediction Technical Valuation Financials Earnings Should I Buy News & Events

Most Trusted AI Platform for Winning Trades

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

Home
Contact
About Us
Press
Privacy
Terms of Service
Service Terms of Use

Resources

Blog
Tutorial
Help Center
Affiliate Program

Markets

Market Analysis
Crypto
Featured Screeners
AI Earnings Calendar
Market Movers
Stock Monitor
Economic Calendar
All US Stocks
All Cryptos

Tools

Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator

Features

QuantAI Alpha Pick
SwingMax Portfolio
Swing Trading
AI Stock Picker
Whales Auto Tracker
Daytrading Center
Patterns Detection
AI Screener
Financial AI Agent
Backtesting Playground
AI Earnings Prediction
Stock Monitor
Technical Analysis

News

Overview
Top News
Daily Market Brief
Earnings Analysis
Newswire
Stock News
Crypto News
Institution News
Congress News
Monitor News

Compare

TradingView
SeekingAlpha

Loading chart...

High

26.000

Open

25.500

VWAP

24.12

Vol

76.84K

Mkt Cap

11.54B

Low

23.030

Amount

1.85M

EV/EBITDA(TTM)

--

Total Shares

494.49M

EV

12.69B

EV/OCF(TTM)

--

P/S(TTM)

--

Regencell Bioscience Holdings Ltd is a bioscience company that focuses on research, development and commercialization of traditional Chinese medicine (TCM) for the treatment of neurocognitive disorders and degeneration, specifically attention deficit and hyperactivity disorder (ADHD) and autism spectrum disorder (ASD). The Company launches three liquid based standardized TCM formulae candidates for mild, moderate and severe ADHD and ASD patients.

Show More

Events Timeline

(ET)

2026-03-30

06:20:00

Regencell Bioscience Files to Sell Ordinary Shares

2026-03-23 (ET)

2026-03-23

12:10:00

Regencell Bioscience Shares Down 8.7% to $25.00

2026-03-18 (ET)

2026-03-18

12:10:00

Regencell Bioscience Stock Rises 15.4% to $26.50

2026-03-18

10:10:00

Regencell Bioscience Stock Rises 26.7% to $29.11

2026-03-09 (ET)

2026-03-09

11:10:00

Regencell Bioscience Holdings Ltd Trading Halted

2026-03-09

10:10:00

Regencell Bioscience Shares Down 7.9% to $21.50

2026-02-13 (ET)

2026-02-13

10:10:00

Regencell Bioscience Stock Rises 18.2% to $34.30

2026-02-03 (ET)

2026-02-03

08:50:00

Regencell Borrow Rate Increases to 192.53%

2026-02-02 (ET)

2026-02-02

10:10:00

Regencell Bioscience Shares Rise 11.6% to $27.89

News

Barron's

U.S. Markets Increased on Monday; QXO Saw the Largest Gain

U.S. Stock Market Performance: Stock indexes in the U.S. experienced gains on Monday, with the S&P 500 rising by 1.38%.
Index Movements: The Dow Jones Industrial Average also increased by 1.38%, while the Nasdaq Composite saw a rise of 1.15%.

Barron's

S&P 500 Futures Hold Steady in Pre-Market Session; Vertex Pharmaceuticals and UFP Industries Take the Lead

Market Opening: U.S. stock markets are set to open in two hours.
Vertex Pharmaceuticals Performance: Vertex Pharmaceuticals Inc. (VRTX) saw a 6.2% increase in pre-market trading.
UFP Industries Performance: UFP Industries Inc. (UFPI) experienced a 5.0% rise in pre-market trading.
Overall Market Sentiment: The pre-market gains indicate positive sentiment among investors for these companies.

Fool

Regencell Bioscience Market Risk Analysis

Staggering Market Capitalization: Regencell Bioscience boasts a market cap nearing $12 billion with a shocking 21,000% stock price increase over the past year, yet investors should exercise caution to avoid being lured by such massive gains.
Research Stage Risks: As an early-stage bioscience company, Regencell focuses on traditional Chinese medicine (TCM) research, and despite operating for 14 years, it has yet to secure any patented drugs, highlighting the uncertainty and high risks associated with its R&D efforts.
Lack of Marketable Products: The company's annual report clearly states that Regencell has no saleable products and has not generated any revenue from product sales, raising concerns about its future viability as a going concern.
Cautious Investment Advice: Given the absence of products and the high-risk nature of its business, investors are advised to steer clear of Regencell and consider established companies like Pfizer that have a robust portfolio of patented drugs to mitigate investment risks.

NASDAQ.COM

03-07NASDAQ.COM

Regencell Bioscience Faces High-Risk Investment Landscape

Remarkable Market Capitalization: Regencell Bioscience boasts a market cap nearing $12 billion, with its stock surging 21,000% over the past year, yet investors are advised to tread carefully and not be lured by such massive price gains.
Lack of Marketable Products: Since its inception in 2014, the company has failed to find any marketable drugs and has not generated revenue from product sales, which significantly heightens the investment risk in the bioscience sector.
Focus on Traditional Chinese Medicine: Regencell's emphasis on Traditional Chinese Medicine (TCM) lacks the appeal of patented drugs, making it less attractive compared to more established pharmaceutical companies that have proven portfolios.
Cautious Investment Recommendations: Analysts recommend that investors thoroughly understand the drug candidates being researched by Regencell before considering stock purchases, given the high-risk nature of the investment.

Yahoo Finance

03-07Yahoo Finance

Regencell Bioscience Investment Warning

Surprising Market Cap: Regencell Bioscience boasts a market capitalization nearing $12 billion, with a staggering 21,000% stock price increase over the past year, yet investors are advised to tread carefully to avoid being lured by such massive gains, given the high-risk nature of the biotech sector.
Slow R&D Progress: Despite being established in 2014 and focusing on Traditional Chinese Medicine (TCM), Regencell has yet to secure any patented drugs or generate revenue from product sales, highlighting the significant uncertainty surrounding its research outcomes.
Significant Investment Risks: The lack of marketable products and the focus on TCM render Regencell a high-risk investment, suggesting that most investors should opt for established pharmaceutical companies with a portfolio of patented drugs to mitigate investment risks.
Market Competition Analysis: Compared to large pharmaceutical firms like Pfizer, Regencell's investment appeal appears minimal, as Pfizer is heavily investing in the GLP-1 space and possesses a robust portfolio of patented drugs to bolster its competitive edge.

Fool

Regencell Bioscience: A High-Risk Investment in TCM

High-Risk Investment: Regencell Bioscience focuses on the research and development of Traditional Chinese Medicine (TCM) for treating neurocognitive disorders and infectious diseases, yet with no products currently in regulatory approval, the investment risk remains extremely high.
Funding Needs: As an early-stage bioscience company, Regencell requires substantial capital to support its R&D activities, posing a risk to investors who may face capital losses if the research fails, making it suitable only for the most aggressive investors.
Market Performance: Currently, Regencell's stock has dropped by 4.01%, with a price of $24.43 and a market cap of $13 billion, reflecting market concerns about its future prospects, especially in the absence of any products.
Industry Competition: While TCM may present a promising research avenue, larger pharmaceutical companies are likely to explore this space more thoroughly, potentially placing Regencell at a competitive disadvantage due to its narrow focus.

Valuation Metrics

The current forward P/E ratio for Regencell Bioscience Holdings Ltd (RGC.O) is 0.00, compared to its 5-year average forward P/E of 0.00. For a more detailed relative valuation and DCF analysis to assess Regencell Bioscience Holdings Ltd's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

dotted line Image

N/A

5Y Average PE

0.00

Current PE

0.00

Overvalued PE

0.00

Undervalued PE

0.00

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

dotted line Image

N/A

5Y Average EV/EBITDA

0.00

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.00

Undervalued EV/EBITDA

0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

dotted line Image

N/A

5Y Average PS

0.00

Current PS

0.00

Overvalued PS

0.00

Undervalued PS

0.00

Financials

AI Analysis

Annual

Quarterly

Related Community Screener

stocks gain $5.00 in 2026

Intellectia · 2622 candidates

Year Price Change Pct: >= $0.01

Ticker

Name

Market Cap$

AXT Inc

3.80B

Palatin Technologies Inc

35.18M

Regencell Bioscience Holdings Ltd

12.08B

Relmada Therapeutics Inc

639.83M

Babcock & Wilcox Enterprises Inc

1.95B

Terns Pharmaceuticals Inc

5.44B

bullish stocks this week

Intellectia · 56 candidates

Market Cap: >= 4.00BRegion: USList Exchange: XNYS, XNAS, XASEMoving Average Relationship: PriceAboveMA20Week Price Change Pct: >= $10.00Monthly Average Dollar Volume: >= 1,000,000

Ticker

Name

Market Cap$

Masimo Corp

9.43B

Immunitybio Inc

8.41B

Ondas Inc

4.98B

Moderna Inc

18.21B

elf Beauty Inc

5.20B

Kratos Defense and Security Solutions Inc

17.84B

ابي سهم التارقت حقي يكون اجيب فوق 25% واعلى من راس مالي

Intellectia · 1346 candidates

Year Price Change Pct: >= $25.00

Ticker

Name

Market Cap$

Regencell Bioscience Holdings Ltd

13.54B

Palatin Technologies Inc

28.78M

Rich Sparkle Holdings Ltd

875.38M

Abivax SA

8.86B

Sandisk Corp

97.55B

Hycroft Mining Holding Corporation

3.20B

what’s a good buy for day trading

Intellectia · 2418 candidates

Region: USPrice: $2.00 - $200.00Volume: >= 200,000List Exchange: XNYS, XNAS, XASE

Ticker

Name

Market Cap$

AstraZeneca PLC

298.35B

Planet Green Holdings Corp

30.35M

Aquestive Therapeutics Inc

509.36M

Perspective Therapeutics Inc

351.47M

Ascent Solar Technologies Inc

29.36M

PAVmed Inc

9.16M

entonces que acciones?

Intellectia · 74 candidates

Market Cap: >= 3.00BRsi Category: moderateWeek Price Change Pct: $5.00 - $20.00Ema 20: >= -100Ema 60: >= -100Monthly Average Dollar Volume: >= 1,000,000

Ticker

Name

Market Cap$

Sasol Ltd

4.76B

Lemonade Inc

6.97B

Telecom Argentina SA

5.50B

Companhia de Saneamento Basico do Estado de Sao Paulo - SABESP

18.55B

Korea Electric Power Corp

27.73B

Posco Holdings Inc

19.18B

Intellectia · 2866 candidates

Pe Ttm: <= 10

Ticker

Name

Market Cap$

SL Green Realty Corp

3.35B

Avadel Pharmaceuticals PLC

2.11B

HubSpot Inc

15.84B

Arrowhead Pharmaceuticals Inc

9.42B

PDF Solutions Inc

1.42B

Trivago NV

197.86M

what stocks is up more than 500%

Intellectia · 22 candidates

Weekly Average Turnover: >= 1,000,000Year Price Change Pct: >= $500.00

Ticker

Name

Market Cap$

Sandisk Corp

73.47B

Regencell Bioscience Holdings Ltd

10.83B

Abivax SA

9.41B

Celcuity Inc

4.96B

Terns Pharmaceuticals Inc

3.99B

Hycroft Mining Holding Corporation

3.22B

Whales Holding RGC

Trading Trends

Insider

Hedge Fund

Congress Trading

People Also Watch

Frequently Asked Questions

What is Regencell Bioscience Holdings Ltd (RGC) stock price today?

The current price of RGC is 23.33 USD — it has decreased -9.12

What is Regencell Bioscience Holdings Ltd (RGC)'s business?

Regencell Bioscience Holdings Ltd is a bioscience company that focuses on research, development and commercialization of traditional Chinese medicine (TCM) for the treatment of neurocognitive disorders and degeneration, specifically attention deficit and hyperactivity disorder (ADHD) and autism spectrum disorder (ASD). The Company launches three liquid based standardized TCM formulae candidates for mild, moderate and severe ADHD and ASD patients.

What is the price predicton of RGC Stock?

Wall Street analysts forecast RGC stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for RGC is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Regencell Bioscience Holdings Ltd (RGC)'s revenue for the last quarter?

Regencell Bioscience Holdings Ltd revenue for the last quarter amounts to NaN USD, decreased

What is Regencell Bioscience Holdings Ltd (RGC)'s earnings per share (EPS) for the last quarter?

Regencell Bioscience Holdings Ltd. EPS for the last quarter amounts to USD, decreased

How many employees does Regencell Bioscience Holdings Ltd (RGC). have?

Regencell Bioscience Holdings Ltd (RGC) has 10 emplpoyees as of March 31 2026.

What is Regencell Bioscience Holdings Ltd (RGC) market cap?

Today RGC has the market capitalization of 11.54B USD.